Table 1.

Characteristics of 62 patients with DPLN treated with prednisolone and either MMF or CTX-AZAa

MMF and PrednisoloneCTX-AZA and PrednisoloneTotalP Value
No. of patients323062
Age (yr)38.1 ± 10.241.8 ± 8.939.9 ± 10.00.073
Female/male26/626/452/100.733
Follow-up (mo)52.2 ± 19.763.9 ± 17.657.8 ± 18.70.103
Baseline parameters
    serum creatinine
        mg/dl1.27 ± 0.741.28 ± 0.531.28 ± 0.640.976
        μmol/L112.7 ± 65.8113.1 ± 46.9112.9 ± 57.0
    proteinuria (g/24 h)6.21 ± 4.114.44 ± 3.625.32 ± 3.940.082
    serum albumin (g/L)27.6 ± 6.727.5 ± 3.827.5 ± 5.40.983
    creatinine clearance (ml/min)67.4 ± 22.674.9 ± 25.971.8 ± 24.60.305
    activity score8.6 ± 2.59.0 ± 2.88.8 ± 2.70.893
    chronicity score3.1 ± 2.53.2 ± 2.23.2 ± 2.40.990
  • a DPLN, diffuse proliferative lupus nephritis; MMF, mycophenolate mofetil; CTX-AZA, cyclophosphamide-azathioprine.